• 1
    Fiser SM, Tribble CG, Long SM, et al. Ischemia–reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73: 10411047.
  • 2
    Ailawadi G, Lau CL, Smith PW, et al. Does reperfusion injury still cause significant mortality after lung transplantation? J Thorac Cardiovasc Surg 2009; 137: 688694.
  • 3
    Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart–Lung Transplantation Report—2009. J Heart Lung Transplant 2009; 28: 10311049.
  • 4
    Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127: 161165.
  • 5
    Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 26: 10041011.
  • 6
    Sharma AK, LaPar DJ, Zhao Y, et al. Natural killer T cell-derived IL-17 mediates lung ischemia–reperfusion injury. Am J Respir Crit Care Med 2011; 183: 15391549.
  • 7
    LaPar DJ, Hajzus VA, Zhao Y, et al. Acute hyperglycemic exacerbation of lung ischemia–reperfusion injury is mediated by receptor for advanced glycation end-products signaling. Am J Respir Cell Mol Biol 2012; 46: 299305.
  • 8
    Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010; 2010: 917108.
  • 9
    Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clin Biochem 2011; 44: 601604.
  • 10
    Englert JM, Ramsgaard L, Valnickova Z, Enghild JJ, Oury TD. Large scale isolation and purification of soluble RAGE from lung tissue. Protein Expr Purif 2008; 61: 99101.
  • 11
    Hanford LE, Enghild JJ, Valnickova Z, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004; 279: 5001950024.
  • 12
    Lutterloh EC, Opal SM, Pittman DD, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11: R122.
  • 13
    Yan SF, Ramasamy R, Schmidt AM, Soluble RAGE. therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010; 79: 13791386.
  • 14
    Sternberg DI, Gowda R, Mehra D, et al. Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. J Thorac Cardiovasc Surg 2008; 136: 15761585.
  • 15
    Su X, Looney MR, Gupta N, Matthay MA. Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1L5.
  • 16
    Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 10101015.
  • 17
    Calfee CS, Budev MM, Matthay MA, et al. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007; 26: 675680.
  • 18
    Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367388.
  • 19
    Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7: 17.
  • 20
    Shelton MD, Mieyal JJ. Regulation by reversible S-glutathionylation: Molecular targets implicated in inflammatory diseases. Mol Cells 2008; 25: 332346.
  • 21
    Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia–reperfusion. J Exp Med 2005; 201: 11351143.
  • 22
    Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248251.
  • 23
    Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 29502954.
  • 24
    Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. Mol Med 2008; 14: 476484.
  • 25
    Tsung A, Klune JR, Zhang X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204: 29132923.
  • 26
    Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 2575225761.
  • 27
    Harris HE, Raucci A. Alarmin(g) news about danger: Workshop on innate danger signals and HMGB1. EMBO Rep 2006; 7: 774778.
  • 28
    van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 9199.
  • 29
    Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: A double-edged sword. Cancer Cell 2007; 12: 300301.
  • 30
    Harris HE, Andersson U, Pisetsky DS. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012; 8: 195202.
  • 31
    Akirav EM, Preston-Hurlburt P, Garyu J, et al. RAGE expression in human T cells: A link between environmental factors and adaptive immune responses. PLoS ONE 2012; 7: e34698.
  • 32
    Chen Y, Akirav EM, Chen W, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 2008; 181: 42724278.
  • 33
    Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173: 10081015.
  • 34
    Yan SS, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003; 9: 287293.
  • 35
    Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 16231626.
  • 36
    Constien R, Forde A, Liliensiek B, et al. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 2001; 30: 3644.
  • 37
    Yang Z, Sharma AK, Linden J, Kron IL, Laubach VE. CD4+ T lymphocytes mediate acute pulmonary ischemia–reperfusion injury. J Thorac Cardiovasc Surg 2009; 137: 695702; discussion.
  • 38
    Sharma AK, Fernandez LG, Awad AS, Kron IL, Laubach VE. Proinflammatory response of alveolar epithelial cells is enhanced by alveolar macrophage-produced TNF-alpha during pulmonary ischemia–reperfusion injury. Am J Physiol Lung Cell Mol Physiol 2007; 293: L105L113.
  • 39
    Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 2010; 24: 10431055.
  • 40
    Reddy MA, Li SL, Sahar S, et al. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J Biol Chem 2006; 281: 1368513693.
  • 41
    Wang X, Sun R, Wei H, Tian Z. High-mobility group box 1 (HMGB1)-toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of γδ T cells with macrophages. Hepatology 2012; 57: 373384.
  • 42
    Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012; 488: 670674.
  • 43
    Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139162.
  • 44
    Willingham SB, Allen IC, Bergstralh DT, et al. NLRP3 (NALP3, cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol 2009; 183: 20082015.
  • 45
    Chang Y, Huang X, Liu Z, et al. Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro. J Surg Res 2013; 181: 308314.
  • 46
    Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 1194211947.
  • 47
    Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases. Mol Med 2007; 13: 625635.
  • 48
    Koyama H, Yamamoto H, Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2007; 2: 331339.
  • 49
    Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia–reperfusion injury of the heart. Circulation 2008; 117: 32163226.
  • 50
    Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005; 78: 18.
  • 51
    Liu A, Fang H, Dirsch O, Jin H, Dahmen U. Oxidation of HMGB1 causes attenuation of its pro-inflammatory activity and occurs during liver ischemia and reperfusion. PLoS ONE 2012; 7: e35379.
  • 52
    Hodge G, Hodge S, Li-Liew C, Reynolds PN, Holmes M. Increased natural killer T-like cells are a major source of pro-inflammatory cytokines and granzymes in lung transplant recipients. Respirology 2012; 17: 155163.
  • 53
    Snell GI, Levvey BJ, Zheng L, et al. Interleukin-17 and airway inflammation: A longitudinal airway biopsy study after lung transplantation. J Heart Lung Transplant 2007; 26: 669674.
  • 54
    Verleden SE, Vos R, Vandermeulen E, et al. Involvement of interleukin-17 during lymphocytic bronchiolitis in lung transplant patients. J Heart Lung Transplant 2013; 32: 447453.
  • 55
    Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 34983506.